Decade of Daddy Mirror Fund™ update

For those with a passing interest in the Decade of Daddy Mirror Fund™ (see prior post “Decade of Daddy Mirror Fund™ Quarterly Report” Jan 7-10), we had $660k of cash sitting around so I added it to the existing Bristol Myers Squibb (BMY:NYSE) position at US$26.01 on the basis that research analysts are forecasting good earnings growth, and management just bumped the dividend a snick. I can’t quite tell whether the current U.S. Healthcare legislative dynamic is good or bad for BMY, but rest assured people will still need drugs when the machinations in Washington come to an end.

I know it is too early for the regular quarterly report, but for those who can’t wait: NAV is at $46.6 million, a new high for the fund; up 16.6% since inception.

MRM